{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:51:46Z","timestamp":1789696306640,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.ijpharm.2012.01.026","type":"journal-article","created":{"date-parts":[[2012,1,28]],"date-time":"2012-01-28T19:28:19Z","timestamp":1327778899000},"page":"100-107","source":"Crossref","is-referenced-by-count":87,"title":["Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells"],"prefix":"10.1016","volume":"426","author":[{"given":"R.P.","family":"Aquino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Prota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Auriemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mencherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2012.01.026_bib0005","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1023\/A:1013082531394","article-title":"Use of solid corrugated particles to enhance powder aerosol performance","volume":"18","author":"Chew","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11095-004-9020-4","article-title":"How much particle surface corrugation is sufficient to improve aerosol performance of powders?","volume":"22","author":"Chew","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0015","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","article-title":"Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis","volume":"163","author":"Clancy","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0020","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1164\/ajrccm.160.5.9810080","article-title":"Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study","volume":"160","author":"Crowther Labiris","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0025","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jcf.2008.06.002","article-title":"Anti-inflammatory effect of miglustat in bronchial epithelial cells","volume":"7","author":"Dechecchi","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0030","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1002\/jps.22173","article-title":"Albumin\/gentamicin microspheres produced by supercritical assisted atomization: optimization of size, drug loading and release","volume":"99","author":"Della Porta","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0035","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00109-002-0363-1","article-title":"Aminoglycoside suppression of a premature stop mutation in a Cftr\u2212\/\u2212 mouse carrying a human CFTR-G542X transgene","volume":"80","author":"Du","year":"2002","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0040","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4187\/aarc0537","article-title":"Aerosol antibiotics in cystic fibrosis","volume":"54","author":"Geller","year":"2009","journal-title":"Respir. Care"},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0045","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/jps.20315","article-title":"The effect of water to ethanol feed ratio on physical properties and aerosolization behavior of spray dried cromolyn sodium particles","volume":"94","author":"Gilani","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0050","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/ajcn\/41.5.1061","article-title":"Whole body protein turnover in malnourished cystic fibrosis patients and its relationship to pulmonary disease","volume":"41","author":"Holt","year":"1985","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijpharm.2009.10.029","article-title":"Development of inhalable dry powder formulation of basic fibroblast growth factor","volume":"385","author":"Ibrahim","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0060","first-page":"324","article-title":"Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers","volume":"53","author":"Khassawneh","year":"2008","journal-title":"Respir. Care"},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jps.21078","article-title":"Trileucine improves aerosol performance and stability of spray-dried powders for inhalation","volume":"97","author":"Lechuga-Ballesteros","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0070","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/jgm.654","article-title":"The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy","volume":"7","author":"Li","year":"2005","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0075","first-page":"761","article-title":"Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum","volume":"132","author":"Mendelman","year":"1985","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0080","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/thx.51.4.364","article-title":"Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks","volume":"51","author":"Mukhopadhyay","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0085","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s11095-009-9825-2","article-title":"Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency","volume":"26","author":"Parlati","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","article-title":"Formulation strategy and use of excipients in pulmonary drug delivery","volume":"392","author":"Pilcer","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0095","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/MCP.0b013e32833eebfd","article-title":"Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity","volume":"16","author":"Prayle","year":"2010","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijpharm.2011.03.055","article-title":"Leucine enhances aerosol performance of naringin dry powder and its activity on cystic fibrosis airway epithelial cells","volume":"412","author":"Prota","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis inhaled tobramycin study group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0110","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejpb.2008.10.007","article-title":"Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying","volume":"72","author":"Sansone","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0115","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v24.i4.10","article-title":"Spray-dried powders for pulmonary drug delivery","volume":"24","author":"Seville","year":"2007","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0120","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1002\/jps.21362","article-title":"Cospray-dried unfractionated heparin with l-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy","volume":"97","author":"Shur","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0125","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1515\/JPEM.2009.22.5.417","article-title":"Insulin-like growth factor-I levels predict weight, height and protein catabolism in children and adolescents with cystic fibrosis","volume":"22","author":"Switzer","year":"2009","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijpharm.2010.01.014","article-title":"Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims","volume":"389","author":"Thai","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0135","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s11095-007-9475-1","article-title":"Pharmaceutical particle engineering via spray drying","volume":"25","author":"Vehring","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2009.03.020","article-title":"Characterization of a new inhalable thymopentin formulation","volume":"375","author":"Wang","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0145","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/jps.21849","article-title":"Force control and powder dispersibility of spray dried particles for inhalation","volume":"99","author":"Weiler","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0150","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1164\/ajrccm.161.3.9904116","article-title":"A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations","volume":"161","author":"Wilschanski","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0155","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations","volume":"349","author":"Wilschanski","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpharm.2012.01.026_bib0160","doi-asserted-by":"crossref","first-page":"L844","DOI":"10.1152\/ajplung.00355.2002","article-title":"Development of cystic fibrosis and noncystic fibrosis airway cell lines","volume":"284","author":"Zabner","year":"2003","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517312000609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517312000609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T15:59:35Z","timestamp":1543247975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517312000609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":32,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0378517312000609"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2012.01.026","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}